Cystic fibrosis

Lancet

Volumn 361, Issue 9358, 2003, Pages 681-689

  Ratjen, Felix ^a   Döring, Gerd ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORIDE CHANNEL;

AUTOSOMAL RECESSIVE DISORDER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; EPITHELIUM CELL; GENE MUTATION; GENE REPLACEMENT THERAPY; GENETIC CODE; HAEMOPHILUS INFLUENZAE; HUMAN; LIFE EXPECTANCY; LUNG DISEASE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

EID: 0037460729     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12567-6     Document Type: Conference Paper

References (140)

1. Riordan J.R., Rommens J.M., Kerem B.S., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 245:1989;1066-1073.
2. Rommens J.M., Iannuzzi M.C., Kerem B.S., et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 245:1989;1059-1065.
3. Zielinski J., Rozmahel R., Bozon D., et al. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator. Genomics. 10:1991;241-248.
4. Collins F.S. Cystic fibrosis: molecular biology and therapeutic implications. Science. 256:1992;774-779.
5. The Cystic Fibrosis Genetic Analysis Consortium. Cystic Fibrosis Mutation Data Base. http://www.genet.sickkids.on.ca/cftr/ (accessed Nov 26, 2002).
6. Vankeerberghen A., Cuppens H., Cassiman J.J. The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions. J Cystic Fibrosis. 1:2002;13-29.
7. Correlation between genotype and phenotype in cystic fibrosis. N Engl J Med. 329:1993;1308-1313.
8. Morral N., Bertranpetit J., Estivill X., et al. The origin of the major cystic fibrosis mutation (delta F508) in European populations. Nat Genet. 7:1994;169-175.
9. Lester L.A., Kraut J., Lloyd-Still J., et al. Delta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population. Pediatrics. 93:1994;114-118.
10. Bronsveld I., Mekus F., Bijman J., et al. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest. 108:2001;1705-1715.
11. Aron Y., Polla B.S., Bienvenu T., et al. HLA class II polymorphism in cystic fibrosis: a possible modifier of pulmonary phenotype. Am J Respir Crit Care Med. 159:1999;1464-1468.
12. Grasemann H., Knauer N., Eijmes J., et al. Airway NO levels in CF patients are related to a polymorphism in the neuronal NO synthase (NOS1) gene. Am J Respir Crit Care Med. 162:2000;2172-2176.
13. Döring G., Krogh-Johansen H., Weidinger S., et al. Allotypes of alpha1-antitrypsin in cystic fibrosis patients homozygous and heterozygous for delta F508. Pediatr Pulmonol. 18:1994;3-7.
14. Mahadeva R., Sharples L., Ross-Russell R.I., et al. Association of alpha(1)-antichymotrypsin deficiency with milder lung disease in patients with cystic fibrosis. Thorax. 56:2001;53-58.
15. Garred P., Pressler T., Madsen H.O., et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest. 104:1999;431-437.
16. 2-adrenoreceptor polymorphisms as modifiers of lung disease in cystic fibrosis. Pharmacogenetics. 12:2002;347-353.
17. Zielenski J., Corey M., Rozmahel R., et al. Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet. 22:1999;128-129.
18. Boucher R., Cotton C.U., Gatzy J.T., et al. Evidence for reduced Cl- and increased Na+ permeability in cystic fibrosis human primary cell cultures. J Physiol. 404:1988;77-103.
19. Schwiebert E.M., Morales M.M., Devidas S., et al. Chloride channel and chloride conductance regulator domains of CFTR, the cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci USA. 95:1998;2674-2689.
20. Reddy M.M., Light M.J., Quinton P.M. Activation of the epithelial Na+ channel (ENaC) requires CFTR Cl- channel function. Nature. 402:1999;301-304.
21. Knowles M.R., Clarke L.L., Boucher R.C. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med. 325:1991;533-538.
22. -. Nat Med. 7:2001;292-293.
23. Cystic Fibrosis Foundation Patient Registry Annual Report. 2000;2001 Cystic Fibrosis Foundation, Bethesda.
24. Khan T.Z., Wagener J.S., Bost T., et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 151:1995;1075-1082.
25. Zahm J.M., Gaillard D., Dupuit F., et al. Early alterations in airway mucociliary clearance and inflammation of the lamina propria in CF mice. Am J Physiol. 272:1997;C853-C859.
26. Tirouvanziam R., de Bentzmann S., Hubeau C., et al. Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol. 23:2000;121-127.
27. Armstrong D.S., Grimwood K., Carlin J.B., et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 156:1997;1197-1204.
28. Bonfield T.L., Konstan M.W., Burfeind P., et al. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol. 13:1995;257-261.
29. Chmiel J.F., Konstan M.W., Knesebeck J.E., et al. IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice. Am J Respir Crit Care Med. 160:1999;2040-2047.
30. Poschet J.F., Boucher J.C., Tatterson L., et al. Molecular basis for defective glycosylation and Pseudomonas pathogenesis in cystic fibrosis lung. Proc Natl Acad Sci USA. 98:2001;13972-13977.
31. Imundo L., Barasch J., Prince A., et al. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci USA. 92:1995;3019-3023.
32. Pier G.B., Grout M., Zaidi T.S., et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science. 271:1996;64-67.
33. Smith J.J., Travis S.M., Greenberg E.P., et al. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell. 85:1996;229-236.
34. Widdicombe J.H. Altered NaCl concentration of airway surface liquid in cystic fibrosis. Pflügers Arch Eur J Physiol. 443:(suppl 1):2001;S8-S10.
35. Bals R., Weiner D.J., Meegalla R.L., et al. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest. 103:1999;1113-1117.
36. Jayaraman S., Song Y., Vetrivel L., et al. Noninvasive in vivo fluorescence measurement of airway-surface liquid depth, salt concentration, and pH. J Clin Invest. 107:2001;317-324.
37. Matsui H., Grubb B.R., Tarran R., et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 95:1998;1005-1015.
38. Worlitzsch D., Tarran R., Ulrich M., et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest. 109:2002;317-325.
39. Mathee K., Ciofu O., Sternberg C., et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology. 145:1999;1349-1357.
40. Konstan M.W., Hilliard K.A., Norvell T.M., et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med. 150:1994;448-454.
41. Kopelman H., Durie P., Gaskin K., et al. Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis. N Engl J Med. 312:1985;329-334.
42. Fried M.D., Durie P.R., Tsui L.C., et al. The cystic fibrosis gene and resting energy expenditure. J Pediatr. 119:1991;913-916.
43. Lanng S., Thornsteinsson B., Lund-Anderen C., et al. Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications. Acta Paediatr. 83:1994;72-77.
44. Holl R.W., Wolf A., Thon A., et al. Insulin resistance with altered secretory kinetics and reduced proinsulin in cystic fibrosis patients. J Pediatr Gastroenterol Nutr. 25:1997;188-193.
45. Dodge J.A. Male fertility in cystic fibrosis. Lancet. 346:1995;587-588.
46. Kopito L.E., Kosasky H.J., Shwachman H. Water and electrolytes in cervical mucus from patients with cystic fibrosis. Fertil Steril. 24:1973;512-516.
47. Rosenstein B.J., Cutting G.R. The diagnosis of cystic fibrosis: a consensus statement. J Pediatr. 132:1998;589-595.
48. Stern R.C. Current concepts: the diagnosis of cystic fibrosis. N Engl J Med. 336:1997;487-491.
49. Wilmott R.W. Making the diagnosis of cystic fibrosis. J Pediatr. 132:1998;563-565.
50. Veeze H.J., Sinaasappel M., Bijman J., et al. Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis. Gastroenterology. 101:1991;398-3403.
51. Bush A., Wallis C. Time to think again: cystic fibrosis is not an "all or none" disease. Pediatr Pulmonol. 30:2000;139-144.
52. Barbero G.J., Sibinga M.S., Marino J.M. Stool trypsin and chymotrypsin: value in the diagnosis of pancreatic insufficiency in cystic fibrosis. Am J Dis Child. 112:1966;536-540.
53. Phillips I.J., Rowe D.J., Dewar P., et al. Faecal elastase 1: a marker of exocrine pancreatic insufficiency in cystic fibrosis. Ann Clin Biochem. 36:1999;739-742.
54. Gharib R., Allen R.P., Joos H.A., et al. Paranasal sinuses in cystic fibrosis: incidence of roentgen abnormalities. Am J Dis Child. 108:1964;499-502.
55. Dörk T., Dworniczak B., Aulehla-Scholz C., et al. Distinct spectrum of CFTR mutations in congenital absence of vas deferens. Hum Genet. 100:1997;365-377.
56. Merelle M.E., Lees C.M., Nagelkerke A.F., et al. Newborn screening for cystic fibrosis (Cochrane Review). Cochrane Database Syst Rev. 3:2001;CD001402.
57. Scotet V., de Braekeleer M., Roussey M., et al. Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis. Lancet. 356:2000;789-794.
58. Farrell P.M., Kosorok M.R., Laxova A., et al. Nutritional benefits of neonatal screening for cystic fibrosis. N Engl J Med. 337:1997;963-969.
59. Farrell P.M., Kosorok M.R., Rock M.J., et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Pediatrics. 107:2001;1-13.
60. Elborn J.S., Bell S.C. Nutrition and survival in cystic fibrosis. Thorax. 51:1996;971-972.
61. Farrell P.M., Shen G., Splaingard M., et al. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. Pediatrics. 100:1997;E2.
62. Flotte T.R., Laube B.L. Gene therapy in cystic fibrosis. Chest. 120:2001;124S-131S.
63. Knowles M.R., Hohneker K.W., Zhou Z., et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med. 333:1995;823-831.
64. Alton E.W., Stern M., Farley R., et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet. 353:1999;947-954.
65. Zabner J., Ramsey B.W., Meeker D.P., et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest. 97:1996;1504-1511.
66. Hamilton J.W. Gentamicin in pharmocogenetic approach to treatment of cystic fibrosis. Lancet. 358:2001;2014-2016.
67. Cheng S.H., Gregory R.J., Marshall J., et al. Defective intracellular traffic and processing of CFTR is the molecular basis of most cystic fibrosis. Cell. 63:1990;827-834.
68. Zhang F., Kartner N., Lukacs G.L. Limited proteolysis as a probe for arrested conformational maturation of delta F508 CFTR. Nat Struct Biol. 5:1998;180-183.
69. Kalin N., Claass A., Sommer M., et al. DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis. J Clin Invest. 103:1999;1379-1389.
70. Penque D., Mendes F., Beck S., et al. Cystic fibrosis F508del patients have apically localized CFTR in a reduced number of airway cells. Lab Invest. 80:2000;857-868.
71. Andersson C., Roomans G.M. Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX. Eur Respir J. 15:2000;937-941.
72. Rubenstein R.C., Zeitlin P.L. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med. 157:1998;484-490.
73. McCarty N.A., Standaert T.A., Teresi M., et al. A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatr Pulmonol. 33:2002;90-98.
74. Galietta L.V., Jayaraman S., Verkman A.S. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol. 281:2001;C1734-C1742.
75. Wang F., Zeltwanger S., Hu S., et al. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels. J Physiol. 524:2000;637-648.
76. Knowles M.R., Church N.L., Waltner W.E., et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med. 322:1990;1189-1194.
77. Knowles M.R., Clarke L.L., Boucher R.C. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med. 325:1991;533-538.
78. Rodgers H.C., Knox A.J. The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis. Eur Respir J. 14:1999;693-696.
79. Noone P.G., Hamblett N., Accurso F., et al. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol. 32:2001;122-128.
80. Döring G. Management of infection in cystic fibrosis. Hosp Pharm. 5:2002;65-69.
81. Høiby N., Koch C. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax. 45:1990;881-884.
82. Fitzsimmons F.C. The changing epidemiology of cystic fibrosis. J Pediatr. 122:1993;1-9.
83. Szaff M., Hoiby N. Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis. Acta Paediatr Scand. 71:1982;21-26.
84. Kahl B., Herrmann M., Everding A.S., et al. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis. 177:1998;1023-1029.
85. Weaver L.T., Green M.R., Nicholson K., et al. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child. 70:1994;84-89.
86. Ratjen F., Comes G., Paul K., et al. Effect of continuous anti-staphylococcal therapy on the rate of P aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol. 31:2001;13-16.
87. Stutman H.R., Lieberman J.M., Nussbaum E., et al. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr. 140:2002;299-305.
88. Smyth A., Walters S. Prophylactic antibiotics for cystic fibrosis (Cochrane Review). Cochrane Database Syst Rev. 2:2000;CD001021.
89. Oliver A., Canton R., Campo P., et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science. 288:2000;1251-1254.
90. Döring G., Conway S.P., Heijerman H.G., et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 16:2000;749-767.
91. Barclay M.L., Begg E.J., Chambers S.T., et al. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother. 37:1996;1155-1164.
92. Breen L., Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev. 4:2001;CD002767.
93. Frederiksen B., Lanng S., Koch C., et al. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol. 21:1996;153.
94. Elborn J.S., Prescott R.J., Stack B.H., et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax. 55:2000;355-358.
95. Steinkamp G., Tümmler H., Gappa M., et al. Long-term tobramycin inhalation in cystic fibrosis. Pediatr Pulmonol. 6:1989;91-98.
96. Jensen T., Pedersen S.S., Garne S., et al. Colistin inhalation therapy in cystic fibrosis patients with chronic P aeruginosa infection. J Antimicrob Chemother. 19:1987;831-838.
97. Ramsey B.W., Pepe M.S., Quan J.M., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 340:1999;23-30.
98. Ryan G., Mukhopadhyay S., Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis (Cochrane Review). Cochrane Database Syst Rev. 2:2000;CD001021.
99. Kudoh S., Azuma A., Yamamoto M., et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 157:1998;1829-1832.
100. Jaffe A., Francis J., Rosenthal M., et al. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet. 351:1998;420.
101. Wolter J., Seeney S., Bell S., et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 57:2002;212-216.
102. Equi A., Balfour-Lynn I., Bush A., Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 360:2002;978-984.
103. Southern K.W., Barker P.M., Solis A. Macrolide antibiotics for cystic fibrosis (Cochrane Review). Cochrane Database Syst Rev. 3:2000;CD002203.
104. Littlewood J.M., Miller M.G., Ghoneim A.T., et al. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet. 1:1985;865.
105. Valerius N.H., Koch C., Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation by early treatment. Lancet. 338:1991;725-726.
106. Wiesemann H.G., Steinkamp G., Ratjen F., et al. Placebo-controlled double-blind randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Pediatr Pulmonol. 26:1998;88-92.
107. Ratjen F., Döring G., Nikolaizik W. Eradication of Pseudomonas aeruginosa with inhaled tobramycin in patients with cystic fibrosis. Lancet. 358:2001;983-984.
108. Auerbach H.S., Willaims M., Kirkpatrick J.A., et al. Alternate-day prednisone reduces morbitity and improves pulmonary function in cystic fibrosis. Lancet. 2:1985;686-688.
109. Eigen H., Rosenstein B.J., Fitzsimmons S., et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr. 126:1995;515-523.
110. Lai H.C. FitzSimmons SC, Allen DB, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med. 342:2000;851-859.
111. Cheng K., Ashby D., Smyth R. Oral steroids for cystic fibrosis (Cochrane Review). Cochrane Database Syst Rev. 2:2000;CD000407.
112. Dezateux C., Walters S., Balfour-Lynn I. Inhaled corticosteroids for cystic fibrosis (Cochrane Review). Cochrane Database Syst Rev. 2:2000;CD001915.
113. Konstan M.W., Byard P.J., Hoppel C.L., et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 332:1995;848-854.
114. Döring G., Knight R., Bellon G. Immunology of cystic fibrosis. Hodson M.E., Geddes D. Cystic fibrosis. 2000;109-141 Arnold, London.
115. McElvaney N.G., Nakamura H., Birrer P., et al. Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 90:1992;1296-1301.
116. McElvaney N.G., Doujaiji B., Moan M.J., et al. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis. 148:1993;1056-1060.
117. 1-antitrypsin treatment for cystic fibrosis. Lancet. 337:1991;392-394.
118. Cantin A.M., Woods D.E. Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Am J Respir Crit Care Med. 160:1999;1130-1135.
119. Ratjen F., Wönne R., Posselt H.G., et al. A double-blind placebo controlled trial with oral ambroxol and n-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr. 144:1985;374-378.
120. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 331:1994;637-642.
121. Quan J.M., Tiddens H.A., Sy J.P., et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr. 139:2001;813-820.
122. Kearney C.E., Wallis C.E. Deoxyribonuclease for cystic fibrosis (Cochrane Review). Cochrane Database Syst Rev. 2:2000;CD001127.
123. Suri R., Metcalfe C., Lees B., et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet. 358:2001;1316-1321.
124. Wark P.A., McDonald V. Nebulised hypertonic saline for cystic fibrosis (Cochrane Review). Cochrane Database Syst Rev. 2:2000;CD001506.
125. Bennet L.E., Keck B.M., Daily O.P., et al. Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT international Registry for Thoracic Organ Transplantation. Clin Transpl. 1:2000;31-44.
126. Liou T.G., Adler F.R., Cahill B.C., et al. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA. 286:2001;2683-2689.
127. Aurora P., Whitehead B., Wade A., et al. Lung transplantation and life extension in children with cystic fibrosis. Lancet. 354:1999;1591-1593.
128. Aris R.M., Routh J.C., LiPuma J.J., et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex: survival linked to genomovar type. Am J Respir Crit Care Med. 164:2001;2102-2106.
129. Kerem E., Reisman J., Corey M., et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 326:1992;1187-1191.
130. Cohen R.G., Starnes V.A. Living donor lung transplantation. World J Surg. 25:2001;244-250.
131. Gaskin K., Gurwitz D., Durie P., et al. Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption. J Pediatr. 100:1982;857-862.
132. Corey M., McLaughlin F.J., Williams M., et al. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol. 41:1988;583-591.
133. Sinaasappel M., Stern M., Littlewood J., et al. Nutrition in patients with cystic fibrosis: a European consensus. J Cystic Fibrosis. 1:2002;51-75.
134. Smyth R., Walters S. Oral calorie supplements for cystic fibrosis (Cochrane Review). Cochrane Database Syst Rev. 2:2000;CD000406.
135. Conway S.P., Morton A., Wolfe S. Enteral tube feeding for cystic fibrosis (Cochrane Review). Cochrane Database Syst Rev. 2:2000;CD001198.
136. Cheng K., Ashby D., Smyth R. Ursodeoxycholic acid for cystic fibrosis-related liver disease (Cochrane Review). Cochrane Database Syst Rev. 2:2000;CD000222.
137. Milkiewicz P., Skiba G., Kelly D., et al. Transplantation for cystic fibrosis: outcome following early liver transplantation. J Gastroenterol Hepatol. 17:2002;208-213.
138. Fogarthy A., Hubbard R., Britton J. International comparison of median age at death from cystic fibrosis. Chest. 117:2000;1656-1660.
139. Mahadeva R., Westerbeck Webb K., et al. Clinical outcome in relation to care in centers specialising in cystic fibrosis: cross sectional study. 1998;1771-1775 BMJ Publishing, London.
140. Schechter M.S., Shelton B.J., Margolis P.A., et al. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med. 163:2001;1331-1337.